Fungi Now: Timely Insights for Sharper Clinical Decision Making

Prof. Martin Hoenigl is an Associate Professor for Translational Mycology at the Division of Infectious Diseases, Medical University of Graz, Austria. His research interests focus on clinical mycology, including fungal diagnostics, host-fungal pathogen interactions, and pharmacology of antifungal drugs. He has worked in mycology for over 15 years, and has published over 350 scientific papers. He is the past president of the European Confederation of Medical Mycology (ECMM), and serves an editor for several leading mycology journals.

Received research funding from Basilea, Gilead, Elion, F2G, GSK, IMMY, Pulmocide, Melinta, Mundipharma, Pharmaholdings, Shionogi and Scynexis.

Dr Souha Kanj is a Professor of Medicine at the American University of Beirut Medical Center (AUBMC), and Chair of the Infection Control Program, co-Chair of the Antimicrobial Stewardship Program, and Consulting Professor at Duke University Medical Center. Her research focuses on nosocomial infections, antimicrobial resistance and stewardship, nosocomial infections, infection control, ID during wars, and fungal infections. She has co-authored over 325 peer-reviewed articles, book chapters, and UpToDate® cards. She serves as an advisory member for WHO programs in infection control, antimicrobial resistance, priority pathogens, diagnostic stewardship, COVID-19, and fungal infections.

Honoraria for speaker and advisory board member for Menarini, MSD, Pfizer, Hikma, Gilead. Author of UpTodate cards. Participated in ECMM guidelines.

Prof. Johan Maertens is a hematologist and Associate Professor at University Hospitals Leuven, Belgium. His work focuses on invasive fungal diseases, particularly in immunocompromised patients. He has authored more than 450 scientific publications, is a founding member and current chair of the European Conference on Infections in Leukaemia (ECIL), a past chair of the EORTC Infectious Diseases Group, and a Fellow of the European Confederation of Medical Mycology.

Grants or contracts from F2G, Gilead, MSD, Mundipharma, Pfizer. Consulting fees from Abbvie, Servier, Basilea, Takeda, Daiichi Sankyo, Cidara, Asahi Kasei Pharma Corporation, Gilead, Elion Therapeutics, Novo Nordisk, MedPace, Menarini, Mundipharma, Pfizer, Scynexis, Shionogi, Biosergen and Octapharma. Speaker and lecture honoraria from Takeda, Abbvie, Gilead, Medscape/WebMD, MSD, Mundipharma, Pfizer, Shionogi. Payment for expert testimony from Cidara, Mundipharma and F2G.

Prof. George Dimopoulos is a Professor of Pulmonary and Critical Care Medicine at the National and Kapodistrian University of Athens, Head of the 3rd University Department of Critical Care at EVGENIDIO Hospital and Consultant in Critical Care in Therapeutic Clinic at ALEXANDRA Hospital, all in Greece. He has authored more than 300 scientific papers and reviews and contributed to more than 70 book chapters. He is a former chair of the Respiratory Infections Assembly of the European Respiratory Society (ERS) and Infection Section of the European Society of Intensive Care Medicine (ESICM), a past Education Officer of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Critically Ill Patients, and a Fellow of the European Confederation of Medical Mycology (ECMM).

Advisory boards: Menarini, Gilead, MSD and VERMA Drugs.

Prof. Ignacio Martin-Loeches is a Professor of Intensive Care Medicine at Trinity College Dublin and Consultant at St James’s Hospital, Ireland. He specializes in severe infection, sepsis, and ICU acquired respiratory disease and has authored more than 600 peer reviewed publications, including on critical care guidelines and translational infection science. He serves as Chair of the Critical Care Group at the European Respiratory Society and Chair of Research at the European Society of Intensive Care Medicine, currently leads the ERS European Network for ICU-related Respiratory Infections, and is a former Steering Committee member of the Surviving Sepsis Campaign.

Received funding from Gilead, MSD, Mundipharma, Pfizer and Thermofisher.